GlassScriptPhysician profile
Sashi Naidu
NPI 1245327279
$52,271.61
in general payments reported to CMS, 2019-2025
92 companies · $3,596 in 2025
The $3,596 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $8,601 · 2021: $4,510 · 2022: $8,409 · 2023: $5,048 · 2024: $5,927 · 2025: $3,596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $2,310 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,418 · Education: $117 · Travel and Lodging: $24.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,701.82 |
| Consulting Fee | $2,310.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,417.50 |
| Education | $116.99 |
| Travel and Lodging | $24.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $5,419.19 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Genentech USA, INC. | $5,376.90 | 2019-2025 | Polivy, Venclexta, Lunsumio |
| Astrazeneca Pharmaceuticals LP | $5,176.74 | 2019-2025 | Imfinzi, Calquence, Tagrisso |
| Novartis Pharmaceuticals Corporation | $4,104.31 | 2019-2025 | |
| Labcorp Holdings INC. | $3,294.06 | 2022 | |
| Secura Bio, INC. | $2,778.39 | 2019-2020 | |
| Sobi, INC | $2,700.31 | 2022-2025 | |
| Fresenius Kabi USA, LLC | $1,750.00 | 2021 | |
| Genmab U.S., INC. | $1,570.26 | 2023-2025 | Epkinly, Tivdak |
| Morphosys, US INC. | $1,466.44 | 2021-2022 | |
| Janssen Biotech, INC. | $1,165.78 | 2019-2025 | Erleada, Rybrevant, Carvykti |
| Merck Sharp & Dohme LLC | $1,165.62 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $1,120.19 | 2019-2025 | Opdivo |
| Bayer Healthcare Pharmaceuticals INC. | $1,113.24 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $1,073.07 | 2019-2025 | Tavalisse |
Show all 89 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,025.45 | 2019-2025 | |
| Daiichi Sankyo INC. | $750.65 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Taiho Oncology, INC. | $681.56 | 2019-2025 | |
| Abbvie INC. | $668.55 | 2019-2025 | |
| Eisai INC. | $592.39 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $589.00 | 2019-2025 | Alunbrig, Iclusig, Fruzaqla |
| Amgen INC. | $543.24 | 2019-2023 | Nplate, Vectibix, Xgeva |
| Lilly USA, LLC | $432.76 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Glaxosmithkline, LLC. | $385.76 | 2021-2025 | Ojjaara, Jemperli, Shingrix |
| Karyopharm Therapeutics INC. | $367.26 | 2020-2025 | Xpovio |
| Exelixis INC. | $362.71 | 2019-2024 | Cabometyx |
| Genzyme Corporation | $337.40 | 2019-2025 | |
| Seagen INC. | $325.88 | 2019-2023 | Adcetris, Padcev |
| Pharmacosmos Therapeutics INC. | $308.25 | 2021-2025 | Monoferric, Cosela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.19 | 2019-2025 | Gilotrif |
| Astellas Pharma US INC | $250.79 | 2019-2025 | Padcev, Xtandi |
| Regeneron Healthcare Solutions, INC. | $247.48 | 2021-2025 | Libtayo |
| Celgene Corporation | $242.26 | 2020-2024 | Pomalyst, Reblozyl |
| Adaptive Biotechnologies Corporation | $227.06 | 2022-2025 | Clonoseq |
| Array Biopharma INC | $225.26 | 2020-2025 | Braftovi, Mektovi, Lorbrena |
| Kite Pharma, INC. | $208.98 | 2020-2024 | Yescarta |
| Pharmacyclics LLC, An Abbvie Company | $206.04 | 2021-2023 | Imbruvica |
| Alexion Pharmaceuticals, INC. | $199.62 | 2022-2025 | Ultomiris, Soliris |
| Cti Biopharma Corp. | $196.76 | 2022-2023 | Vonjo |
| Puma Biotechnology, INC. | $196.67 | 2019-2025 | |
| Gilead Sciences, INC. | $189.83 | 2019-2025 | Trodelvy |
| Beigene USA, INC. | $169.07 | 2022-2024 | Brukinsa |
| Global Blood Therapeutics, INC. | $160.39 | 2020-2022 | |
| Pharmaessentia USA Corporation | $143.52 | 2022-2025 | Besremi |
| Jazz Pharmaceuticals INC. | $129.09 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $112.98 | 2021 | |
| Coherus Oncology, INC. | $107.77 | 2020-2023 | |
| Servier Pharmaceuticals LLC | $107.03 | 2022-2024 | |
| Dova Pharmaceuticals | $105.82 | 2020-2021 | |
| Celltrion USA INC. | $105.28 | 2023-2024 | Vegzelma |
| Beone Medicines USA, INC. | $94.47 | 2025 | Brukinsa |
| Oxford Gene Technology INC | $93.61 | 2023 | |
| Aveo Pharmaceuticals, INC. | $90.78 | 2022-2024 | Fotivda |
| Deciphera Pharmaceuticals INC. | $90.00 | 2022-2024 | Qinlock |
| Stemline Therapeutics INC. | $85.15 | 2023-2025 | Orserdu, Elzonris |
| Adc Therapeutics America, INC. | $78.37 | 2024-2025 | |
| Emd Serono, INC. | $73.60 | 2019-2025 | Bavencio |
| Azurity Pharmaceuticals, INC. | $67.43 | 2025 | Danziten |
| Tersera Therapeutics LLC | $64.54 | 2025 | Xermelo, Quzyttir |
| Acrotech Biopharma INC. | $64.52 | 2022-2024 | Beleodaq |
| Spectrum Pharmaceuticals INC. | $63.71 | 2023-2025 | Rolvedon |
| Amneal Pharmaceuticals LLC | $61.34 | 2024-2025 | Avastin, Alymsys |
| Ipsen Biopharmaceuticals, INC | $60.50 | 2021-2024 | Onivyde, Somatuline Depot |
| Sandoz INC. | $59.34 | 2024-2025 | Cyclophosphamide, Ziextenzo |
| Sun Pharmaceutical Industries INC. | $59.10 | 2019-2022 | |
| Kyowa Kirin, INC. | $57.09 | 2023-2025 | Poteligeo |
| Eusa Pharma (US) LLC | $52.47 | 2022 | |
| Epizyme, INC. | $50.43 | 2021-2022 | |
| Octapharma USA, INC. | $46.39 | 2019 | |
| Mylan Institutional INC. | $39.48 | 2019-2020 | |
| G1 Therapeutics, INC. | $38.39 | 2022 | |
| Heron Therapeutics, INC. | $38.22 | 2020 | |
| Organon LLC | $37.54 | 2022 | |
| Csl Behring | $37.22 | 2024 | Hemgenix |
| Foundation Medicine, INC. | $29.59 | 2023 | |
| Janssen Pharmaceuticals, INC | $29.40 | 2021-2022 | |
| Cycle Pharmaceuticals INC | $26.39 | 2025 | Phyrago |
| Geron Corporation | $24.42 | 2025 | Rytelo |
| Tg Therapeutics, INC. | $21.98 | 2022 | |
| Novocure INC. | $21.47 | 2024 | Optune Lua (Novottf-200t) |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Fennec Pharmaceuticals, INC. | $20.48 | 2024 | Pedmark |
| Tolmar Pharmaceuticals, INC. | $19.73 | 2022 | |
| Tempus Ai, INC | $18.98 | 2025 | Xt Cdx |
| Amag Pharmaceuticals, INC. | $15.88 | 2021 | |
| Immunocore Limited | $15.20 | 2024 | Kimmtrak |
| Myriad Genetic Laboratories, INC. | $14.44 | 2024 | Myrisk |
| Lexicon Pharmaceuticals, INC. | $14.04 | 2019 | |
| Shire North American Group INC | $13.67 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,698.10 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sashi Naidu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.